In one paragraphArticle in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
21 authors.
Timothy P DiPeriDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1190-1640 Kurt W EvansDepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0008-6823-6809 Stephen ScottDepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0002-2910-4287 Xiaofeng ZhengDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0007-2171-7210 Kaushik VaradarajanDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4114-5498 Lawrence N KwongDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8370-1432 Michael KahleDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5982-3832 Hop S Tran CaoDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8612-8272 Ching-Wei TzengDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6035-7288 Fei SuDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5834-4074 Maria Gabriela RasoDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2105-5556 Yasmeen RizviDepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0000-2719-4093 Ming ZhaoDepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0005-9985-4448 Huamin WangDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2038-5863 Sunyoung S LeeDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5954-5991 Timothy A YapDepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2154-3309 Jordi RodonDepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6467-3632 Milind JavleDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9158-0941 Funda Meric-BernstamDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6816-6072 Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MConvalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3MCenter for Clinical and Translational SciencesUM1TR004906 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Maria Eulalia Fernandez, LORNA H. MCNEILL · 2024 to 2026
$16.7MTRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2MUniversity of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MERIC-BERNSTAM, FUNDA, ROTH, JACK · 2017 to 2022
$7.7MNational Cancer Institute (NCI) P30CA016672National Center for Advancing Translational Sciences (NCATS) UM1TR004906National Institutes of Health (NIH) T32CA009599NCATS NIH HHS UL1 TR003167NCATS NIH HHS UM1 TR004906NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA009599NCI NIH HHS U54 CA224065
6 · The paper itselfAbstract
purposeBiliary tract cancers, which are rare and aggressive malignancies, are rich in clinically actionable molecular alterations. A major challenge in the field is the paucity of clinically relevant biliary tract cancer models that recapitulate the diverse molecular profiles of these tumors. The purpose of this study was to curate a collection of patient-derived xenograft (PDX) models that reflect the spectrum of genomic alterations present in biliary tract cancers to create a resource for modeling precision oncology. EXPERIMENTAL
designPDXs were derived from biliary tract cancer samples collected from surgical resections or metastatic biopsies. Alterations present in the PDXs were identified by whole-exome sequencing and RNA sequencing. PDXs were treated with approved and investigational agents. Efficacy was assessed by change in tumor volume from baseline. Event-free survival was defined as the time to tumor doubling from baseline. Responses were categorized at day 21: >30% decrease in tumor volume = partial response, >20% increase in tumor volume = progressive disease, and any non-partial response/progressive disease was considered stable disease.
resultsGenomic sequencing demonstrated key actionable alterations across this cohort, including alterations in FGFR2, isocitrate dehydrogenase I, ERRB2, PIK3CA, PTEN, and KRAS. RNA sequencing demonstrated fusions and expression of antibody-drug conjugate targets, including TROP2, HER2, and Nectin4. Therapeutic matching revealed objective responses to approved and investigational agents that have been shown to have antitumor activity clinically.
conclusionsIn this study, we developed a catalog of biliary tract cancer PDXs that underwent comprehensive molecular profiling and therapeutic modeling. To date, this is one of the largest collections of biliary tract cancer PDX models and will facilitate the development of personalized treatments for patients with these aggressive malignancies.
Indexed as
Biliary Tract NeoplasmsBiomarkers, TumorPrecision MedicineAnimalsDisease Models, AnimalExome SequencingFemaleHumansMaleMiceMutationXenograft Model Antitumor AssaysBiomarkers, Tumor
Identifiers
PMID39513959
PMCPMC11739782
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390